Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kenji Oritani is active.

Publication


Featured researches published by Kenji Oritani.


Genomics | 1995

Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth

Jun Ishikawa; Tsuneyasu Kaisho; Hitoshi Tomizawa; Byung Ok Lee; Yoshiko Kobune; Johji Inazawa; Kenji Oritani; Motoyuki Itoh; Takahiro Ochi; Katsuhiko Ishihara; Toshio Hirano

Bone marrow stromal cells regulate B-cell growth and development through their surface molecules and cytokines. In this study, we generated a mAb, RS38, that recognized a novel human membrane protein, BST-2, expressed on bone marrow stromal cell lines and synovial cell lines. We cloned a cDNA encoding BST-2 from a rheumatoid arthritis-derived synovial cell line. BST-2 is a 30- to 36-kDa type II transmembrane protein, consisting of 180 amino acids. The BST-2 gene (HGMW-approved symbol BST2) is located on chromosome 19p13.2. BST-2 is expressed not only on certain bone marrow stromal cell lines but also on various normal tissues, although its expression pattern is different from that of another bone marrow stromal cell surface molecule, BST-1. BST-2 surface expression on fibroblast cell lines facilitated the stromal cell-dependent growth of a murine bone marrow-derived pre-B-cell line, DW34. The results suggest that BST-2 may be involved in pre-B-cell growth.


Molecular and Cellular Biology | 1997

Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5.

Itaru Matsumura; Jun Ishikawa; Koichi Nakajima; Kenji Oritani; Yoshiaki Tomiyama; Jun-ichiro Miyagawa; Takashi Kato; Hiroshi Miyazaki; Yuji Matsuzawa; Yuzuru Kanakura

Although thrombopoietin (TPO) is known to play a fundamental role in both megakaryopoiesis and thrombopoiesis, the molecular mechanism of TPO-induced megakaryocytic differentiation is not known. In a human megakaryoblastic leukemia cell line, CMK, that showed some degree of megakaryocytic differentiation after culture with TPO, the cyclin-dependent kinase (Cdk) inhibitor p21(WAF1/Cip1), but not p27(Kip1), p16(INK4A), p15(INK4B), or p18(INK4C), was found to be upregulated in an immediately early response to TPO. The expression of p21 was found to be sustained over a period of 5 days by treatment with TPO in large polyploid cells that developed in response to TPO, but not in small undifferentiated cells, indicating a close correlation between the ligand-induced differentiation and p21 induction in CMK cells. To examine potential roles of Cdk inhibitors in megakaryocytic differentiation, CMK cells were transfected with the p21, p27, or p16 gene, together with a marker gene, beta-galactosidase, and were cultured with medium alone for 5 days. The ectopic expression of p21 or p27 but not of p16 led to induction of megakaryocytic differentiation of CMK cells. Overexpression of the N-terminal domain (amino acids [aa] 1 to 75) of p21 was sufficient to induce megakaryocytic differentiation, whereas that of the C-terminal domain (aa 76 to 164) had little or no effect on morphological features. Furthermore, we found that although TPO induced tyrosine phosphorylation of both STAT3 and STAT5 in CMK cells, only STAT5 showed binding activities to potential STAT-binding sites that locate in the promoter region of p21 gene (p21-SIE sites), thereby leading to transactivation of p21. These results suggested that p21 induction, possibly mediated through activated STAT5, could play an important role in TPO-induced megakaryocytic differentiation.


Journal of Clinical Investigation | 2002

Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins

Takafumi Yokota; C. S. Reddy Meka; Kay L. Medina; Hideya Igarashi; Masahiko Takahashi; Makoto Nishida; Kenji Oritani; Jun-ichiro Miyagawa; Tohru Funahashi; Yoshiaki Tomiyama; Yuji Matsuzawa; Paul W. Kincade

Adiponectin, an adipocyte-derived hormone, was recently shown to have potential therapeutic applications in diabetes and obesity because of its influence on glucose and lipid metabolism. We found that brown fat in normal human bone marrow contains this protein and used marrow-derived preadipocyte lines and long-term cultures to explore potential roles in hematopoiesis. Recombinant adiponectin blocked fat cell formation in long-term bone marrow cultures and inhibited the differentiation of cloned stromal preadipocytes. Adiponectin also caused elevated expression of cyclooxygenase-2 (COX-2) by these stromal cells and induced release of prostaglandin E(2) (PGE(2)). The COX-2 inhibitor Dup-697 prevented the inhibitory action of adiponectin on preadipocyte differentiation, suggesting involvement of stromal cell-derived prostanoids. Furthermore, adiponectin failed to block fat cell generation when bone marrow cells were derived from B6,129S(Ptgs2tm1Jed) (COX-2(+/-)) mice. These observations show that preadipocytes represent direct targets for adiponectin action, establishing a paracrine negative feedback loop for fat regulation. They also link adiponectin to the COX-2-dependent PGs that are critical in this process.


Nature Medicine | 2000

Limitin : An interferon-like cytokine that preferentially influences B-lymphocyte precursors

Kenji Oritani; Kay L. Medina; Yoshiaki Tomiyama; Jun Ishikawa; Yu Okajima; Megumu Ogawa; Takahumi Yokota; Keisuke Aoyama; Isao Takahashi; Paul W. Kincade; Yuji Matsuzawa

We have identified an interferon-like cytokine, limitin, on the basis of its ability to arrest the growth of or kill lympho–hematopoietic cells. Limitin strongly inhibited B lymphopoiesis in vitro and in vivo but had little influence on either myelopoiesis or erythropoiesis. Because limitin uses the interferon α/β receptors and induces interferon regulatory factor-1, it may represent a previously unknown type I interferon prototype. However, preferential B-lineage growth inhibition and activation of Janus kinase 2 in a myelomonocytic leukemia line have not been described for previously known interferons.


Journal of Immunology | 2003

Adiponectin, a Fat Cell Product, Influences the Earliest Lymphocyte Precursors in Bone Marrow Cultures by Activation of the Cyclooxygenase-Prostaglandin Pathway in Stromal Cells

Takafumi Yokota; C. S. Reddy Meka; Taku Kouro; Kay L. Medina; Hideya Igarashi; Masahiko Takahashi; Kenji Oritani; Tohru Funahashi; Yoshiaki Tomiyama; Yuji Matsuzawa; Paul W. Kincade

Adiponectin, an adipocyte-derived hormone, is attracting considerable interest as a potential drug for diabetes and obesity. Originally cloned from human s.c. fat, the protein is also found in bone marrow fat cells and has an inhibitory effect on adipocyte differentiation. The aim of the present study is to explore possible influences on lymphohematopoiesis. Recombinant adiponectin strongly inhibited B lymphopoiesis in long-term bone marrow cultures, but only when stromal cells were present and only when cultures were initiated with the earliest category of lymphocyte precursors. Cyclooxygenase inhibitors abrogated the response of early lymphoid progenitors to adiponectin in stromal cell-containing cultures. Furthermore, PGE2, a major product of cyclooxygenase-2 activity, had a direct inhibitory influence on purified hematopoietic cells, suggesting a possible mechanism of adiponectin action in culture. In contrast to lymphopoiesis, myelopoiesis was slightly enhanced in adiponectin-treated bone marrow cultures, and even when cultures were initiated with single lymphomyeloid progenitors. Finally, human B lymphopoiesis was also sensitive to adiponectin in stromal cell cocultures. These results suggest that adiponectin can negatively and selectively influence lymphopoiesis through induction of PG synthesis. They also indicate ways that adipocytes in bone marrow can contribute to regulation of blood cell formation.


Journal of Immunology | 2006

Modulation of TLR4 Signaling by a Novel Adaptor Protein Signal-Transducing Adaptor Protein-2 in Macrophages

Yuichi Sekine; Tetsuya Yamamoto; Ryuta Muromoto; Seiyu Imoto; Kenji Sugiyma; Kenji Oritani; Kazuya Shimoda; Mayu Minoguchi; Shizuo Akira; Akihiko Yoshimura; Tadashi Matsuda

Signal-transducing adaptor protein-2 (STAP-2) is a recently identified adaptor protein that contains pleckstrin and Src homology 2-like domains as well as a YXXQ motif in its C-terminal region. Our previous studies have demonstrated that STAP-2 binds to STAT3 and STAT5, and regulates their signaling pathways. In the present study, STAP-2 was found to positively regulate LPS/TLR4-mediated signals in macrophages. Disruption of STAP-2 resulted in impaired LPS/TLR4-induced cytokine production and NF-κB activation. Conversely, overexpression of STAP-2 enhanced these LPS/TLR4-induced biological activities. STAP-2, particularly its Src homology 2-like domain, bound to both MyD88 and IκB kinase (IKK)-αβ, but not TNFR-associated factor 6 or IL-1R-associated kinase 1, and formed a functional complex composed of MyD88-STAP-2-IKK-αβ. These interactions augmented MyD88- and/or IKK-αβ-dependent signals, leading to enhancement of the NF-κB activity. These results demonstrate that STAP-2 may constitute an alternative LPS/TLR4 pathway for NF-κB activation instead of the TNFR-associated factor 6-IL-1R-associated kinase 1 pathway.


Journal of Immunology | 2004

Physical and Functional Interactions between Daxx and DNA Methyltransferase 1-Associated Protein, DMAP1

Ryuta Muromoto; Kenji Sugiyama; Akie Takachi; Seiyu Imoto; Noriko Sato; Tetsuya Yamamoto; Kenji Oritani; Kazuya Shimoda; Tadashi Matsuda

Daxx has been shown to play an essential role in type I IFN-αβ-mediated suppression of B cell development and apoptosis. Recently, we demonstrated that Tyk2 is directly involved in IFN signaling for the induction and translocation of Daxx, which may result in growth arrest and/or apoptosis of B lymphocyte progenitors. To clarify how Daxx regulates B cell development, we examined Daxx interacting partners by yeast two-hybrid screening. DNA methyltransferase 1 (DNMT1)-associated protein (DMAP1) was identified and demonstrated to interact with Daxx. The interaction regions in both proteins were mapped, and the cellular localization of the interaction was examined. Both Daxx and DMAP1 formed a complex with DNMT1 and colocalized in the nucleus. DMAP1 enhanced Daxx-mediated repression of glucocorticoid receptor transcriptional activity. Furthermore, Daxx protected protein degradation of DMAP1 in vivo. These results provide the novel molecular link between Daxx and DNMT1, which establishes a repressive transcription complex in the nucleus.


Cytokine & Growth Factor Reviews | 2001

Type I interferons and limitin : a comparison of structures, receptors, and functions

Kenji Oritani; Paul W. Kincade; Cai Zhang; Yoshiaki Tomiyama; Yuji Matsuzawa

The type I interferon (IFN) family includes IFN-alpha, IFN-beta, IFN-pi, and IFN-tau. These molecules are clustered according to sequence homologies, use of the same cell surface receptor, and similar functions. IFN-alpha and IFN-beta have a globular structure composed of five a-helices. Their receptors, IFNAR1 and IFNAR2, belong to the class II cytokine receptor family for a-helical cytokines. Information about structure-function relationships between these and other IFNs is being provided by comparative sequence analysis, reference to a prototypic three-dimensional structure, analysis with monoclonal antibodies, construction of hybrid molecules and site directed mutagenesis. While much remains to be done, it should someday be possible to understand differences among IFNs in terms of how they interact with their corresponding receptors. Our recently identified IFN-like molecule, limitin, has weak sequence homology to IFN-alpha, IFN-beta, and IFN-omega and displays its biological functions through the same IFN-alpha/beta receptors. While limitin has antiproliferative, immunomodulatory, and antiviral effects like IFN-alpha and IFN-beta, it is unique in lacking influence on myeloid and erythroid progenitors. Further analysis of this functionally unique cytokine should be informative about complex IFN-receptor interactions. Furthermore, a human homologue or synthetic variant might be superior for clinical applications as an IFN without myelosuppressive properties.


European Journal of Immunology | 2004

Complement C1q regulates LPS-induced cytokine production in bone marrow-derived dendritic cells.

Masahide Yamada; Kenji Oritani; Tsuneyasu Kaisho; Jun Ishikawa; Hitoshi Yoshida; Isao Takahashi; Shinichirou Kawamoto; Naoko Ishida; Hidetoshi Ujiie; Hiroaki Masaie; Marina Botto; Yoshiaki Tomiyama; Yuji Matsuzawa

We show here that C1q suppresses IL‐12p40 production in LPS‐stimulated murine bone marrow‐derived dendritic cells (BMDC). Serum IL‐12p40 concentration of C1q‐deficient mice was higher than that of wild‐type mice after intraperitoneal LPS‐injection. Because neither globular head of C1q (gC1q) nor collagen‐like region of C1q (cC1q) failed to suppress LPS‐induced IL‐12p40 production, both gC1q and cC1q, and/or some specialized conformation of native C1q may be required for the inhibition. While C1q did not affect mRNA expression of Toll‐like receptor 4 (TLR4), MD‐2, and myeloid differentiation factor 88 (MyD88), BMDC treated with C1q showed the reduced activity of NF‐κB and the delayed phosphorylation of p38, c‐Jun N‐terminal kinase, and extracellular signal‐regulated kinase after LPS‐stimulation. CpG oligodeoxynucleotide‐induced IL‐12p40 and TNF‐α production, another MyD88‐dependent TLR‐mediated signal, was also suppressed by C1q treatment. Therefore, C1q is likely to suppress MyD88‐dependent pathway in TLR‐mediated signals. In contrast, C1q failed to suppress colony formation of B cells responding to LPS or LPS‐induced CD40 and CD86 expression on BMDC in MyD88‐deficient mice, indicating that inhibitory effects of C1q on MyD88‐independent pathways may be limited. Taken together, C1q may regulate innate and adaptive immune systems via modification of signalsmediated by interactions between invading pathogens and TLR.


Journal of Cellular Physiology | 2008

The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells

Yoko Murayama; Yasuhisa Shinomura; Kenji Oritani; Jun-ichiro Miyagawa; Hitoshi Yoshida; Makoto Nishida; Fumie Katsube; Masamichi Shiraga; Tamana Miyazaki; Taisei Nakamoto; Shusaku Tsutsui; Shinji Tamura; Shigeki Higashiyama; Iichirou Shimomura; Norio Hayashi

CD9 is a member of the tetraspanins, and has been shown to be involved in a variety of cellular activities such as migration, proliferation, and adhesion. In addition, it has been known that CD9 can associate with other proteins. Here we demonstrated the physical and functional association of CD9 with epidermal growth factor receptor (EGFR) on MKN‐28 cells. Double‐immunofluorescent staining and immunoprecipitation demonstrated the complex formation of CD9‐EGFR and CD9‐β1 integrin, and that both complexes are colocalized on the cell surface especially at the cell–cell contact site. Anti‐CD9 monoclonal antibody ALB6 induced a dotted or patch‐like aggregation pattern of both CD9‐EGFR and CD9‐β1 integrin. The internalization of EGFR after EGF‐stimulation was significantly enhanced by the treatment with ALB6. CD9 can associate with EGFR in hepatocellular carcinoma cells (HepG2/CD9) and Chinese hamster ovary cancer cells (CHO‐HER/CD9), which were transfected with pTJ/human EGFR/CD9. Furthermore expression of CD9 specifically attenuated EGFR signaling in CHO‐HER/CD9 cells through the down regulation of surface expression of EGFR. These results suggest that CD9 might have an important role that attenuates EGFR signaling. Therefore, CD9 not only associates EGFR but also a new regulator, which may affect EGF‐induced signaling in cancer cells. J. Cell. Physiol. 216: 135–143, 2008.

Collaboration


Dive into the Kenji Oritani's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul W. Kincade

Oklahoma Medical Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Takafumi Yokota

Oklahoma Medical Research Foundation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge